研究者業績

山下 裕玄

ヤマシタ ヒロハル  (Hiroharu Yamashita)

基本情報

所属
自治医科大学 外科学講座消化器一般移植外科部門 教授
学位
博士(医学)(2009年5月 東京大学大学院医学系研究科)

連絡先
yamashita.hiroharujichi.ac.jp
研究者番号
50599397
ORCID ID
 https://orcid.org/0000-0002-9468-3716
J-GLOBAL ID
202101016108721984
Researcher ID
E-7058-2011
researchmap会員ID
R000016168

論文

 233
  • Hirofumi Sonoda, Hideo Ogiso, Yuichi Aoki, Kazue Morishima, Hideki Sasanuma, Naohiro Sata, Joji Kitayama, Hiroharu Yamashita, Hironori Yamaguchi, Ryozo Nagai, Kenichi Aizawa
    Cancers 2026年2月19日  
  • Misaki Matsumiya, Hirofumi Sonoda, Hiroharu Yamashita, Kentaro Kurashina, Kazuya Takahashi, Hideyuki Ohzawa, Hideyo Miyato, Shiro Matsumoto, Shin Saito, Yoshinori Hosoya, Naohiro Sata, Joji Kitayama, Hironori Yamaguchi
    Annals of surgical oncology 2026年1月29日  
    BACKGROUND AND PURPOSE: The peritoneal cavity constitutes a unique immune microenvironment that critically influences the pathobiology of peritoneal metastasis (PM). This study aimed to clarify the mechanisms by which local immune alterations affect the efficacy of intraperitoneal (IP) chemotherapy for PM from gastric cancer (GC). METHOD: Peritoneal lavage or ascitic fluid was obtained from 42 patients with GC and PM treated with IP paclitaxel (PTX) in combination with systemic oxaliplatin and oral S-1. Serial samples from 31 patients were analyzed after 1-3 cycles of chemotherapy. Immune cell subsets were evaluated using multicolor flow cytometry with monoclonal antibodies, and the functional properties of peritoneal eosinophils were assessed using gene expression profiling and cytotoxicity assays. RESULTS: IP chemotherapy was associated with decreased CD4(+) T cells and increased CD11b(+) myeloid cells. Notably, many patients, particularly those with negative cytology (CY0), exhibited striking recruitment of CD66b(+) CD16(-) CD193(+) Siglec-F(+) eosinophils into the peritoneal cavity. Eosinophil expansion was correlated with improved clinical outcomes. Post-treatment eosinophils displayed an activated, partially degranulated phenotype with elevated CD11b and CD63 expression and distinct messenger RNA signatures compared with circulating eosinophils. Peritoneal eosinophils demonstrated the ability to induce apoptosis in GC cells. CONCLUSION: IP PTX promotes the recruitment and activation of eosinophils with potent antitumor activity in the peritoneal cavity. Early post-treatment abdominal eosinophilia is a robust prognostic biomarker and may represent a promising therapeutic target to enhance the efficacy of IP chemotherapy in patients with PM from GC.
  • Matsumoto, Y., Hatakeyama, K., Terashima, M., Nagashima, T., Urakami, K., Shimoda, T., Sugino, T., Bando, E., Yamashita, H., Okamura, Y., Yamaguchi, K.
    Surgical Oncology 64 2026年  
  • Okumura, Y., Narumiya, K., Muraishi, R., Shimamoto, N., Suda, H., Takemura, M., Yamashita, H., Okamura, Y.
    Surgery Today 56(1) 2026年  
  • Hattori, S., Aramaki, O., Watanabe, Y., Kamo, T., Furihata, T., Ushiku, T., Kaneshiro, R., Kasakura, Y., Murayama, I., Yamashita, H., Okamura, Y.
    Journal of the Anus Rectum and Colon 10(2) 2026年  
  • Matsumiya, M., Sonoda, H., Yamashita, H., Yamaguchi, H., Kitayama, J.
    Annals of Surgical Oncology 33(6) 2026年  
  • Boshier, P.R., Chia, D.K.A., Thrumurthy, S.G., Teh, J.L., Wobith, M., Bencivenga, M., Filippini, F., Dumitra, T.C., Burch, M., Kim, H.-I., Kobitzsch, B., Kodach, L.L., Quik, J.S.E., Long, V.D., de Neijs, M.J., van der Sluis, P.C., Leon-Takahashi, A.M., Woo, Y., Chevallay, M., Framarini, M., Morgagni, P., Frejlich, E., Grabsch, H.I., Markar, S.R., Marrelli, D., Park, D.J., Sundar, R., Xu, Z., Linn, K.K., Yang, H.K., Kitayama, J., Zhu, Z., Rha, S.Y., Wijnhoven, B., Yamashita, H., Yong, W.P., de la Fouchardi{\`e}re, C., Nilsson, M., Ishigami, H., Van Sandick, J.W., Lordick, F., Badgwell, B.D., So, J.B.
    British Journal of Surgery 113(4) 2026年  
  • Taguchi, M., Sasanuma, H., Shimodaira, K., Kimura, Y., Aoki, Y., Meguro, Y., Kasahawa, N., Morishima, K., Miyato, H., Ohzawa, H., Miki, A., Kaneda, Y., Endo, K., Koizumi, M., Sakuma, Y., Yamashita, H., Horie, H., Sata, N., Yamaguchi, H.
    Surgical Oncology 65 2026年  
  • Shuichiro Oya, Yasuyoshi Sato, Raito Asaoka, Kotaro Sugawara, Asami Okamoto, Yoshiyuki Miwa, Shoh Yajima, Koichi Yagi, Hiroharu Yamashita, Yoshifumi Baba, Yasuyuki Seto
    Oncology 1-9 2025年12月4日  
    INTRODUCTION: Nivolumab has become an essential therapeutic agent for patients with advanced or recurrent gastric cancer. However, the impact of metastatic patterns on its clinical efficacy has not been fully elucidated. This study aimed to clarify the association between distinct metastatic patterns and outcomes of nivolumab monotherapy. METHODS: Ninety-two patients with advanced or recurrent gastric cancer who received nivolumab were retrospectively analyzed. Clinicopathological variables, including performance status, HER2 expression, and predominant metastatic pattern, were correlated with survival outcomes and response rates. RESULTS: The median observation period was 48.3 months. The median overall (OS) and progression-free (PFS) survival for the entire cohort were 5.80 and 2.43 months, respectively. Patients with ECOG performance status 2-3 had significantly shorter survival than those with PS 0-1. HER2-positive status was associated with longer PFS. When stratified by metastatic pattern, the lymph node metastasis group showed markedly longer survival (median OS 35.1 months, PFS 11.9 months) than the peritoneal (OS 4.66, PFS 2.36 months) and hematogenous/other groups (OS 5.80, PFS 2.10 months). The objective response and disease control rates were also significantly higher in the lymph node group. CONCLUSION: The pattern of metastatic spread, particularly lymphatic involvement, appears to influence the efficacy of nivolumab in advanced or recurrent gastric cancer. Recognizing metastatic patterns may assist in optimizing patient selection and therapeutic strategies for immune checkpoint blockade.
  • Koji Nakada, Hideyuki Kashiwagi, Shinichi Kinami, Hiroharu Yamashita, Nobuyoshi Hanyu, Atsushi Oshio, Michio Kaminishi, Yasuyuki Seto
    Annals of Gastroenterological Surgery 2025年9月  
  • 佐藤 靖祥, 八木 浩一, 鳥海 哲郎, 飯高 さゆり, 黒田 晃弘, 川原 拓也, 谷島 翔, 山下 裕玄, 瀬戸 泰之
    日本食道学会学術集会プログラム・抄録集 79回 137-137 2025年6月  
  • 大矢 周一郎, 佐藤 靖祥, 山下 裕玄, 岡本 麻美, 三輪 快之, 谷島 翔, 八木 浩一, 瀬戸 泰之
    日本胃癌学会総会記事 97回 367-367 2025年3月  
  • Koichi Yagi, Susumu Aikou, Shoh Yajima, Masayuki Urabe, Yasuyohi Sato, Yasuhiro Okumura, Takashi Mitsui, Masato Nishida, Yukinori Yamagata, Hiroharu Yamashita, Sachiyo Nomura, Kazuhiko Mori, Yasuyuki Seto
    Diseases of the Esophagus 38(1) 2025年1月7日  
    Summary We developed a robot-assisted transmediastinal esophagectomy (RATME) to reduce the surgical invasiveness of open transthoracic esophagectomy (oTTE). However, the long-term survival outcomes of patients who undergo RATME remain unclear. Patients who underwent RATME for esophageal squamous cell carcinoma (ESCC) between January 2012 and April 2020 were enrolled. Overall survival (OS), relapse-free survival (RFS), and ESCC cause-specific survival (CSS) were analyzed according to clinical stage. Survivals were compared between patients who underwent the RATME and oTTE using propensity score matching analysis. One hundred and twenty-seven patients who underwent RATME were included in the analysis. The 3- and 5-year OS rates were 96.2 and 92.1% for cStage I RATME group, 84.8 and 82.3% for cStage II, and 61.8 and 61.8% for cStage III, respectively. The 3- and 5-year RFS rates were 94.3 and 84.3% for cStageI, 71.7 and 69.3% for cStage II, and 5 48.2 and 48.2% for cStage III, respectively. Survival analysis using 74 paired patients showed that the RATME group had better OS and RFS than the oTTE group (p = 0.0028 and p = 0.016, respectively), but equivalent CSS (p = 0.078). The OS of the RATME group stratified by clinical stage was equivalent to that of the comprehensive registry data from Japan, and showed better OS and RFS than the oTTE group, indicating that RATME radicality is guaranteed with regard to long-term survival.
  • Toyonaka, R., Aramaki, O., Yoshida, N., Mitsuka, Y., Nakamura, M., Inagaki, S., Murai, K., Ishige, T., Tsujimura, R., Ohni, S., Masuda, S., Yamashita, H., Okamura, Y.
    Japanese Journal of Gastroenterological Surgery 58(6) 2025年  
  • Yuriko Yamada, Shin Saito, Shinichiro Yokota, Yoshinori Hosoya, Hiroharu Yamashita, Hironori Yamaguchi
    Surgical Case Reports 2025年  
  • Hiroyuki Abe, Masayuki Urabe, Koichi Yagi, Hiroharu Yamashita, Yasuyuki Seto, Tetsuo Ushiku
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2024年12月11日  
    BACKGROUND: Recently, novel molecular targeted therapies have been developed for gastric and esophageal adenocarcinomas. We examined the status of therapeutic target molecules in esophagogastric junction (EGJ) and Barrett's adenocarcinoma. METHODS: Tissue microarrays were constructed from 114 cases of non-Barrett's EGJ adenocarcinoma and 30 cases of Barrett's adenocarcinoma. Immunohistochemistry for mismatch repair proteins, PD-L1, HER2, CLDN18, FGFR2b, and EBER-ISH was performed. When HER2 immunohistochemistry was 2 + , gene amplification was examined using in situ hybridization. RESULTS: EBER positivity, mismatch repair deficiency, PD-L1 combined positive score (CPS) ≥ 1, CLDN18 expression ≥ 75%, FGFR2b expression, and HER2 positivity were observed in 7 (6.1%), 11 (9.6%), 70 (61.4%), 38 (33.3%), 6 (5.3%), and 11 (9.6%) cases of EGJ adenocarcinoma as well as in 0 (0%), 0 (0%), 23 (76.7%), 7 (23.3%), 2 (6.7%), and 6 (20.0%) cases of Barrett's adenocarcinoma, respectively. PD-L1 CPS ≥ 1 cases had longer recurrence-free survival (P = 0.001) and overall survival (P = 0.003) than CPS < 1 cases. Other target molecules were not associated with survival. A total of 93/114 (81.6%) cases of EGJ adenocarcinoma and 26/30 (86.7%) cases of Barrett's adenocarcinomas expressed at least one target molecule. CONCLUSIONS: Most EGJ and Barrett's adenocarcinomas may be eligible for molecular targeted therapy. Appropriate patient stratification based on these molecular tests will be important for precision medicine of the EGJ and Barrett's adenocarcinoma.
  • Yasuyoshi Sato, Kazuhiko Mori, Shinichiro Atsumi, Kei Sakamoto, Shuichiro Oya, Asami Okamoto, Masayuki Urabe, Yoshiyuki Miwa, Shoh Yajima, Koichi Yagi, Sachiyo Nomura, Hiroharu Yamashita, Yasuyuki Seto
    Esophagus 2024年7月10日  
    Abstract Background Preoperative chemotherapy with 5-fluorouracil and cisplatin (FP) followed by surgery has been considered a standard treatment for patients with stage II/III esophageal squamous cell carcinoma (ESCC) based on the results of a phase III trial (JCOG9907) in Japan. Subsequently, the phase III NExT trial (JCOG1109) revealed the survival benefit of the neoadjuvant DCF regimen, which adds docetaxel to FP, and it became a standard treatment. However, the long-term results and prognostic factors of neoadjuvant DCF therapy in the real world are unknown. Methods We retrospectively investigated 50 patients with ESCC treated with neoadjuvant DCF therapy from July 2012 to December 2017 at The University of Tokyo Hospital. Results Median overall survival (OS) and progression-free survival (PFS) were 32.3 [95% confidence interval (CI) 21.0–NA] and 10.0 months (95% CI 6.3–15.6), respectively. Median OS [not reached (95% CI 31.5–NA) vs. 21.4 months (95% CI 13.5–33.0); p = 0.028] and PFS [83.3 months (95% CI 6.4–NA) vs. 7.4 months (95% CI 6.0–12.8] were significantly longer in patients with an objective response than in non-responders. Of 44 surgical cases, median PFS tended to be longer in pathological lymph node metastasis-negative patients. Conversely, survival did not differ according to cStage (II/III vs. IV) or the average relative dose intensity (ARDI, ≥ 85% vs. &lt; 85%). Discussion The response to neoadjuvant DCF therapy could predict patient prognosis. Additionally, pN+ tended to increase the recurrence risk, whereas cStage and ARDI did not influence survival.
  • 岡本 麻美, 佐藤 靖祥, 山下 裕玄, 大矢 周一郎, 三輪 快之, 谷島 翔, 八木 浩一, 野村 幸世, 瀬戸 泰之
    日本食道学会学術集会プログラム・抄録集 78回 120-120 2024年7月  
  • 大矢 周一郎, 佐藤 靖祥, 山下 裕玄, 岡本 麻美, 浦辺 雅之, 三輪 快之, 谷島 翔, 八木 浩一, 野村 幸世, 瀬戸 泰之
    日本食道学会学術集会プログラム・抄録集 78回 265-265 2024年7月  
  • YASUYOSHI SATO, HIROHARU YAMASHITA, KOICHI YAGI, SACHIYO NOMURA, YASUYUKI SETO
    Anticancer Research 44(7) 3125-3131 2024年6月26日  
  • 大矢 周一郎, 佐藤 靖祥, 山下 裕玄, 渥美 振一郎, 岡本 麻美, 坂本 啓, 浦辺 雅之, 三輪 快之, 谷島 翔, 八木 浩一, 野村 幸世, 瀬戸 泰之
    日本胃癌学会総会記事 96回 438-438 2024年2月  
  • 岡本 麻美, 佐藤 靖祥, 山下 裕玄, 渥美 振一郎, 大矢 周一郎, 坂本 啓, 浦辺 雅之, 三輪 快之, 谷島 翔, 八木 浩一, 野村 幸世, 瀬戸 泰之
    日本胃癌学会総会記事 96回 436-436 2024年2月  
  • Urabe, M., Okumura, Y., Okamoto, A., Yajima, S., Yagi, K., Yamashita, H., Seto, Y.
    Langenbeck S Archives of Surgery 409(1) 2024年  
  • Hattori, S., Aramaki, O., Watanabe, Y., Kamo, T., Furihata, T., Ushiku, T., Kaneshiro, R., Kasakura, Y., Murayama, I., Yamashita, H., Okamura, Y.
    Journal of the Anus Rectum and Colon 8(4) 2024年  
  • Yasuyoshi Sato, Hiroharu Yamashita, Yukari Kobayashi, Koji Nagaoka, Tetsuro Hisayoshi, Takuya Kawahara, Akihiro Kuroda, Noriyuki Saito, Ryohei Iwata, Yasuhiro Okumura, Koichi Yagi, Susumu Aiko, Sachiyo Nomura, Kazuhiro Kakimi, Yasuyuki Seto
    International journal of molecular sciences 24(23) 2023年11月22日  
    We investigated the tumor immune response in gastric cancer patients receiving third-line nivolumab monotherapy to identify immune-related biomarkers for better patient selection. Nineteen patients (10 males, median age 67 years) who received nivolumab as a third- or later-line therapy were enrolled. We analyzed the tumor immune response in durable clinical benefit (DCB) and non-DCB patients. Pre-treatment and early-on-treatment tumor transcriptomes were examined, and gene expression profiles, immunograms, and T cell receptor (TCR) repertoire were analyzed. DCB was observed in 15.8% of patients, with comparable secondary endpoints (ORR; objective response rate, OS; overall survival, PFS; progression-free survival) to previous trials. The immunograms of individual subjects displayed no significant changes before or early in the treatment, except for the regulatory T cell (Treg) score. Moreover, there were no consistent alterations observed among cases experiencing DCB. The intratumoral immune response was suppressed by previous treatments in most third- or later-line nivolumab recipients. TCR repertoire analysis revealed newly emerged clonotypes in early-on-treatment tumors, but clonal replacement did not impact efficacy. High T cell/Treg ratios and a low UV-radiation-response gene signature were linked to DCB and treatment response. This study emphasizes the tumor immune response's importance in nivolumab efficacy for gastric cancer. High T cell/Treg ratios and specific gene expression signatures show promise as potential biomarkers for treatment response. The tumor-infiltrating immune response was compromised by prior treatments in third-line therapy, implying that, to enhance immunotherapeutic outcomes, commencing treatment at an earlier stage might be preferable. Larger cohort validation is crucial to optimize immune-checkpoint inhibitors in gastric cancer treatment.
  • Masayuki Urabe, Yasuhiro Okumura, Asami Okamoto, Koichi Yagi, Yosuke Tsuji, Hiroharu Yamashita, Mitsuhiro Fujishiro, Yasuyuki Seto
    Nagoya journal of medical science 85(4) 807-813 2023年11月  
    Oncological gastrectomy, despite remaining a mainstay of gastric cancer treatment, is reportedly associated with high morbidity and mortality in elderly patients. Less invasive modalities suitable for senior gastric cancer patients with insufficient surgical tolerance are thus needed. We adopted laparoscopic and endoscopic cooperative surgery as an alternative for elderly gastric cancer cases unsuitable for aggressive gastrectomy. To date, we have experienced three cases (80-86 years old) undergoing palliative laparoscopic and endoscopic cooperative surgery. Postoperative courses were uneventful in two cases, while sutural leakage occurred in the other, which was managed conservatively. Postoperative loss of body weight and skeletal muscle mass appeared to be minimal according to bioelectrical impedance analyses. No gastric cancer recurrence was detected in any of our three cases. As to the balance between radicality and safety, laparoscopic and endoscopic cooperative surgery is potentially a viable option for geriatric gastric cancer patients in whom conventional gastrectomy is contraindicated.
  • Hagiwara, K., Watanabe, Y., Suzuki, T., Okamura, Y., Yamashita, H.
    Annals of Gastroenterological Surgery 7(6) 2023年11月  
  • Yamashita, H., Toyota, K., Kunisaki, C., Seshimo, A., Etoh, T., Ogawa, R., Baba, H., Demura, K., Kaida, S., Oshio, A., Nakada, K.
    Asian Journal of Surgery 46(10) 2023年10月  
  • Shinichiro Shiomi, Koichi Yagi, Ryohei Iwata, Shoh Yajima, Yasuhiro Okumura, Susumu Aikou, Hiroharu Yamashita, Sachiyo Nomura, Yasuyuki Seto
    Surgical Endoscopy 37(11) 8214-8226 2023年8月31日  査読有り
    Abstract Background Lymphatic flow mapping using near-infrared fluorescence (NIR) imaging with indocyanine green (ICG) has been used for the intraoperative prediction of lymph node metastasis in esophageal or esophagogastric junction cancer. However, a consistent method that yields sufficient diagnostic quality is yet to be confirmed. This study explored the diagnostic utility of our newly established lymphatic flow mapping protocol for predicting lymph node metastasis in patients with esophageal or esophagogastric junction cancer. Methods We injected 0.5 mL of ICG (500 μg/mL) into the submucosal layer at four peritumoral points on the day before surgery for 54 patients. We performed lymphatic flow mapping intraoperatively using NIR imaging. After determining the NIR status and presence of metastases, evaluable lymph node stations on in vivo imaging and all resected lymph nodes were divided into four categories: ICG+meta+ (true positive), ICG+meta− (false positive), ICG−meta+ (false negative), and ICG−meta− (true negative). Results The distribution of ICG+ and meta+ lymph node stations differed according to the primary tumor site. Sensitivity and specificity for predicting meta+ lymph nodes among ICG+ ones were 50% (95% CI 41–59%) and 75% (73–76%), respectively. Predicting meta+ lymph node stations among ICG+ stations improved these values to 66% (54–77%) and 77% (74–79%), respectively. Undergoing neoadjuvant chemotherapy was an independent risk factor for having meta+ lymph nodes with false-negative diagnoses (odds ratio 4.82; 95% CI 1.28–18.19). The sensitivity of our technique for predicting meta+ lymph nodes and meta+ lymph node stations in patients who did not undergo neoadjuvant chemotherapy was 79% (63–90%) and 83% (61–94%), respectively. Conclusion Our protocol potentially helps to predict lymph node metastasis intraoperatively in patients with esophageal or esophagogastric junction cancer undergoing esophagectomy who did not undergo neoadjuvant chemotherapy. Graphical abstract
  • Hiroshi Suda, Ryohei Iwata, Ken Hagiwara, Hiroharu Yamashita
    Advances in Digestive Medicine 2023年6月  
  • Satoshi Yamashita, Hiroyuki Abe, Hiroharu Yamashita, Koichi Yagi, Yasuyuki Seto, Tetsuo Ushiku
    Histopathology 83(2) 264-275 2023年4月18日  
    AIMS: Oesophageal small-cell carcinoma is a rare and highly aggressive subtype of oesophageal cancer with a dismal prognosis. To explore the potential applicability of immunotherapy, we investigated the expression status of programmed death ligand 1 (PD-L1) and human leukocyte antigen (HLA)-class I and the degree of tumour-infiltrating lymphocytes (TILs) in oesophageal small-cell carcinoma. METHODS AND RESULTS: PD-L1 and HLA-class I expression levels were evaluated in 10 pure small-cell carcinomas and five mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs). The combined positive score (CPS) and tumour proportion score (TPS) were used for PD-L1 assessment. Immunohistochemistry for mismatch repair (MMR) proteins was also performed. PD-L1 immunohistochemistry demonstrated CPS ≥1 in nine (60%), CPS ≥10 in five (33%), and TPS ≥1 in five (33%) cases. Overall survival was significantly longer in patients with CPS ≥1 than in those with CPS <1. HLA-class I deficiency (>50% tumour cells) was noted in five cases (33%), with no significant correlation with PD-L1 expression status. Among the five MiNENs, HLA-class I expression was decreased in the small-cell carcinoma component of three cases. HLA-class I deficiency was significantly associated with higher TNM stage and reduced TIL levels. MMR deficiency was not observed in any case. CONCLUSION: Given that a significant subset (40%) exhibited PD-L1 CPS ≥1 with preserved HLA-class I expression and high levels of TIL, the PD-1/PD-L1 pathway is a potential therapeutic target for oesophageal small-cell carcinoma.
  • Atsushi Kondo, Aya Shinozaki-Ushiku, Hirofumi Rokutan, Akiko Kunita, Masako Ikemura, Hiroharu Yamashita, Yasuyuki Seto, Genta Nagae, Kenji Tatsuno, Hiroyuki Aburatani, Daizo Koinuma, Tetsuo Ushiku
    The Journal of pathology 2023年2月18日  
    Epstein-Barr virus (EBV) is one of the major drivers of gastric carcinogenesis. EBV infection is established before tumour initiation and is generally maintained throughout tumour development; however, the significance of EBV in tumour maintenance and progression remains to be elucidated. Here, we report eight cases of EBV-associated gastric carcinoma (EBVaGC) with intratumoural heterogenous expression of EBV-encoded small RNA (EBER), a highly expressed latent gene of EBV, and demonstrate clinicopathologic characteristics of these rare cases. By performing detailed histological assessment of EBER-positive and -negative components of each case, detection of EBV genome in tumour cells by fluorescence in situ hybridization, TP73 methylation analysis, whole exome sequencing and targeted gene panel sequencing, we identified tumours in two patients to be collision tumours of different origin. In the other six patients, some genetic/epigenetic alterations were shared between EBER-positive and -negative components, suggesting that EBV is eliminated from tumour cells during progression. Interestingly, in both tumour types, programmed death ligand 1 and intratumoural infiltration of CD8+ T lymphocytes were lower in EBER-negative than in EBER-positive components, suggesting the immunogenic role of EBV. To the best of our knowledge, this study is the first to demonstrate the detailed histological features and genetic/epigenetic alterations in EBVaGC with heterogenous EBER expression; the loss of EBV may benefit tumour progression and immune evasion and might be clinically important for selecting treatment strategies for such cancers. This article is protected by copyright. All rights reserved.
  • Yamagishi, S., Okamura, Y., Kang, W., Shindate, M., Kochi, M., Mitsuka, Y., Watabe, M., Yoshida, N., Ikarashi, M., Yamazaki, S., Aramaki, O., Nakayama, H., Moriguchi, M., Higaki, T., Yamashita, H.
    Digestive Surgery 40(5) 2023年  
  • Masayuki Urabe, Keisuke Matsusaka, Tetsuo Ushiku, Masaki Fukuyo, Bahityar Rahmutulla, Hiroharu Yamashita, Yasuyuki Seto, Masashi Fukayama, Atsushi Kaneda
    Gastric Cancer 2022年10月12日  査読有り
  • Chun-Dong Zhang, Hiroharu Yamashita, Yasuhiro Okumura, Koichi Yagi, Susumu Aikou, Yasuyuki Seto
    Cancers 14(14) 2022年7月13日  
    BACKGROUND: A growing number of studies suggest that the current indications for partial gastrectomy, including proximal gastrectomy and pylorus-preserving gastrectomy (PPG), may be expanded, but evidence is still lacking. METHODS: We retrospectively analyzed 300 patients with gastric cancer (GC) who underwent total gastrectomy. We analyzed the incidence of pLNMs in relation to tumor location, tumor size and T stage. We further identified predictive factors for perigastric lymph node metastasis (pLNM) in stations 1, 2, 3, 4sa, 4sb, 4d, 5, and 6. RESULTS: No patients with upper-third T1-T2 stage GC had pLNMs in stations 4sa, 4sb, 4d, 5, or 6, but 3.8% of patients with stage T3 had 4d pLNM. No patients with upper-third GC < 4 cm in diameter had pLNMs in 2, 4sa, 4d, 5, or 6, and 2.3% of patients had pLNMs in 4sb. For middle-third GCs, 2.9% of patients with T1 stage had pLNMs in 4sa and 5, but no patients with T2 stage or tumors < 4 cm had pLNMs in 2, 4sa, or 5. The shortest distance from pylorus ring to distal edge of tumor (sDPD) was a new predictive factor for pLNMs in 2, 4d, 5, and 6. CONCLUSIONS: Proximal gastrectomy may be expanded to patients with stage T1-T2 GC and/or tumor diameter < 4 cm in the upper-third stomach, whereas PPG may be expanded to include T1-T2/N0 and/or tumors < 4 cm in the middle-third stomach. A new predictive factor, sDPD, showed good predictive performance for pLNMs, especially in stations 4d, 5, and 6.
  • Kotaro Sugawara, Koichi Yagi, Yasuhiro Okumura, Susumu Aikou, Hiroharu Yamashita, Yasuyuki Seto
    World journal of surgery 46(3) 639-647 2022年3月  
    BACKGROUND: Studies have revealed the impacts of various inflammatory and nutritional markers in patients with esophageal squamous cell carcinoma (ESCC). We evaluated the prognostic values of multiple inflammation- or nutrition-based markers, either alone or in combination with pStage, in ESCC patients. METHODS: In total, 360 patients undergoing upfront surgery for ESCC were retrospectively reviewed. The prognostic capabilities of 7 inflammatory and 3 nutritional parameters were investigated. Furthermore, we devised new staging systems by adding these markers to pStage and examined the prognostic abilities of our new approach. Time-dependent receiver operating characteristic curves and the areas under the curve (AUCs) were estimated to compare prognostic capabilities among the parameters. RESULTS: The AUCs for predicting overall survival (OS) of the prognostic nutritional index (PNI), CRP to albumin ration (CAR), lymphocyte to CRP ratio (LCR) and the Naples prognostic score (NPS) were similar to that of pStage. Notably, CAR and LCR showed high predictive capabilities for OS (AUCs; 0.627 and 0.634 for 3-year OS, respectively). New staging systems combining inflammatory or nutritional markers with pStage provided higher AUCs for predicting OS than pStage alone. In particular, NPpStage (NPS and pStage) (P = 0.03), PNpStage (PNI and pStage) (P = 0.03) and LCpStage (LCR and pStage) (P = 0.05) showed significantly higher accuracy for predicting OS than pStage alone. CONCLUSIONS: Various inflammatory or nutritional markers, especially those derived from CRP, are useful for predicting survival outcomes of ESCC patients. The predictive capabilities of these indices were augmented when used in combination with pStage.
  • Daisuke Komura, Akihiro Kawabe, Keisuke Fukuta, Kyohei Sano, Toshikazu Umezaki, Hirotomo Koda, Ryohei Suzuki, Ken Tominaga, Mieko Ochi, Hiroki Konishi, Fumiya Masakado, Noriyuki Saito, Yasuyoshi Sato, Takumi Onoyama, Shu Nishida, Genta Furuya, Hiroto Katoh, Hiroharu Yamashita, Kazuhiro Kakimi, Yasuyuki Seto, Tetsuo Ushiku, Masashi Fukayama, Shumpei Ishikawa
    Cell reports 38(9) 110424-110424 2022年3月1日  
    Cancer histological images contain rich biological and clinical information, but quantitative representation can be problematic and has prevented the direct comparison and accumulation of large-scale datasets. Here, we show successful universal encoding of cancer histology by deep texture representations (DTRs) produced by a bilinear convolutional neural network. DTR-based, unsupervised histological profiling, which captures the morphological diversity, is applied to cancer biopsies and reveals relationships between histologic characteristics and the response to immune checkpoint inhibitors (ICIs). Content-based image retrieval based on DTRs enables the quick retrieval of histologically similar images using The Cancer Genome Atlas (TCGA) dataset. Furthermore, via comprehensive comparisons with driver and clinically actionable gene mutations, we successfully predict 309 combinations of genomic features and cancer types from hematoxylin-and-eosin-stained images. With its mounting capabilities on accessible devices, such as smartphones, universal encoding for cancer histology has a strong impact on global equalization for cancer diagnosis and therapies.
  • Motonari Ri, Hiroharu Yamashita, Wataru Gonoi, Yasuhiro Okumura, Koichi Yagi, Susumu Aikou, Yasuyuki Seto
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 48(2) 377-382 2022年2月  
    BACKGROUND: Advanced gastric cancer with extensive lymph node (LN) metastasis is associated with poor outcomes even after R0 gastrectomy. Although multi-detector row computed tomography (MDCT) is the basis of preoperative LN staging, the diagnostic accuracy of pathologically extensive LN metastasis detection by MDCT remains unsatisfactory. METHODS: We retrospectively evaluated diagnostic accuracy for pN2/3 disease by size and number of depicted LNs on MDCT in a single-center cohort of 421 patients with pT2-4 gastric carcinoma. The positive predictive value (PPV) was determined based on the number and short-axis diameter (SAD) of identified LNs, and oncological outcomes were also evaluated according to clinical LN status and pN categories. RESULTS: The PPV for detecting pN2/3 disease rose with the SAD value cut-off for one LN, reaching 84.6% at 10 mm with no further increase at 15 mm. However, the SAD cut-off value plateaued at 8 mm (91.3%) when at least two measurable LNs were identified on MDCT. Patients with two measurable LNs with SAD≥8 mm had significantly poorer 5-year overall and recurrence-free survival than patients with fewer than two measurable LNs in the pN2-3 disease. On multivariate analysis, two measurable LNs with SAD≥8 mm was an independent prognostic factor for overall and relapse-free survivals. CONCLUSION: Locally advanced gastric cancer with two measurable LNs with SAD≥8 mm on preoperative MDCT is highly associated with pN2/3 disease and poorer outcomes with upfront surgery. This criterion might be a reasonable indicator for identifying candidates for neoadjuvant treatment of advanced gastric cancer.
  • Itamoto, K., Kumamaru, H., Aikou, S., Yagi, K., Yamashita, H., Nomura, S., Miyata, H., Kuroda, S., Fujiwara, T., Endo, S., Kitagawa, Y., Kakeji, Y., Seto, Y.
    Surgery Today 52(6) 2022年  
  • Nakagawa, K., Sho, M., Okada, K.-I., Akahori, T., Aoyama, T., Eguchi, H., Fujii, T., Higuchi, R., Kanaji, S., Kanetaka, K., Kuroda, S., Nagakawa, Y., Nunobe, S., Yamada, S., Yamashita, H., Yamaue, H., Kodera, Y.
    Journal of Gastroenterology 57(2) 2022年  
  • Iwata, R., Shiomi, S., Aikou, S., Yagi, K., Yamashita, H., Seto, Y.
    General Thoracic and Cardiovascular Surgery 70(10) 2022年  
  • Sugawara, K., Yamashita, H., Urabe, M., Uemura, Y., Okumura, Y., Yagi, K., Aikou, S., Seto, Y.
    International Journal of Clinical Oncology 27(12) 2022年  
  • Inagaki, S., Yamazaki, S., Koh, Y., Kochi, M., Ikarashi, M., Mitsuka, Y., Yamagishi, S., Yamashita, H., Takayama, T., Okamura, Y.
    Japanese Journal of Gastroenterological Surgery 55(10) 2022年  
  • Nakagawa, K., Sho, M., Fujishiro, M., Kakushima, N., Horimatsu, T., Okada, K.-I., Iguchi, M., Uraoka, T., Kato, M., Yamamoto, Y., Aoyama, T., Akahori, T., Eguchi, H., Kanaji, S., Kanetaka, K., Kuroda, S., Nagakawa, Y., Nunobe, S., Higuchi, R., Fujii, T., Yamashita, H., Yamada, S., Narita, Y., Honma, Y., Muro, K., Ushiku, T., Ejima, Y., Yamaue, H., Kodera, Y.
    Journal of Gastroenterology 57(12) 2022年  
  • Jin, C., Wakimoto, Y., Ikeda, M., Ohama, Y., Ri, M., Yamashita, H., Ohtani, A., Yamashita, M., Shinohara, T., Jubishi, D., Kanno, Y., Okamoto, K., Higurashi, Y., Harada, S., Okugawa, S., Seto, Y., Moriya, K.
    Journal of Infection and Chemotherapy 28(6) 2022年  
  • Fujisaki, M., Nomura, T., Yamashita, H., Uenosono, Y., Fukunaga, T., Otsuji, E., Takahashi, M., Matsumoto, H., Oshio, A., Nakada, K.
    Journal of Gastric Cancer 22(3) 2022年  
  • Zhang, C.-D., Takeshima, H., Sekine, S., Yamashita, S., Liu, Y.-Y., Hattori, N., Abe, H., Yamashita, H., Fukuda, M., Imamura, Y., Ushiku, T., Katai, H., Makino, H., Watanabe, M., Seto, Y., Ushijima, T.
    Gastric Cancer 25(2) 2022年  査読有り

MISC

 62

講演・口頭発表等

 6

主要な共同研究・競争的資金等の研究課題

 10